Immunotherapy update: Mechanisms of action

Allergy and Asthma Proceedings

Volumn 23, Issue 6, 2002, Pages 373-376

  Greenberger, Paul A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN;

ASTHMA; BRONCHUS HYPERREACTIVITY; CELLULAR IMMUNITY; DESENSITIZATION; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; PHYSIOLOGY; REVIEW; STANDARD; WORLD HEALTH ORGANIZATION;

ASTHMA; BRONCHIAL HYPERREACTIVITY; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULINS; RHINITIS, ALLERGIC, PERENNIAL; WORLD HEALTH ORGANIZATION;

EID: 0036877378     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Durham SR, Walker SM, Varga E-M. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475, 1999.
2. Jacobsen L, Nuchel Petersen B, Wihl JA, et al Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 52:914-920, 1997.
3. Abramson MJ, Puy RM, and Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 151:969-974, 1995.
4. Theodoropoulous DS, and Lockey RF. Allergen immunotherapy: guidelines, update, and recommendations of the World Health Organization. Allergy Asthma Proc 21 159-166, 2000.
5. Bousquet J, Demoly R, and Michel F-B. Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol 87(suppl):38-42, 2001.
6. Bousquet J. Immunotherapy is clinically indicated in the management of allergic asthma Am J Respir Crit Care Med 164:2139-2142, 2001.
7. Greenberger PA. Rush injection therapy for asthma and allergic rhinitis. Ann Allergy 73:378-380, 1994.
8. Adkinson NF Jr, Eggleston PA. Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336: 324-331, 1997.
9. Adkinson NF Jr Immunotherapy is not clinically indicated in the management of allergic asthma Am J Respir Crit Care 164:2140-2141, 2001.
10. Johnstone DE. Immunotherapy in the prevention of allergic disease. Pediatr Asthma Allergy Immunol 1:15-30, 1987.
11. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109:251-256, 2002.
12. Jacobsen L. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol 87(suppl).43-46, 2001.
13. Gleich GJ, Zimmerman EM, Henderson LL, et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 70:261-271, 1982.
14. Djurup R, and Osterbatle O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Allergy 39:433-441, 1984.
15. Platts-Mills TA, von Maur RK, Ishizaka K, et al. IgA and IgG anti-ragweed antibodies in nasal secretions. J Clin Invest 57:1041-1050, 1976.
16. Lichtenstein LM, Norman PS, Winkenwerder WL, et al. In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization. J Clin Invest 45: 1126-1136, 1966.
17. Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma. Ann Allergy Asthma Immunol 87(suppl):13-27, 2001
18. Zeiss CR, Metzger WJ, and Levitz D Quantitative relationships between IgE antibody and blocking antibodies specific for antigen E in patients given immunotherapy with ragweed antigen E. Clin Exp Immunol 28.250-255, 1977
19. Otsuka H, Mezawa A, Ohnishi M, et al. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 21 115-119, 1991.
20. Durham SR, and Till SJ Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102:157-164, 1998.
21. Furin MF, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosmophil cell migration into the nasal cavity. J Allergy Clin Immunol 88.27-32, 1991
22. Rak S, Lowhagen O, and Venge P The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 82.470-480, 1988.
23. Nish WA, Charlesworth EN, Davis TL, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 93:484-493, 1994
24. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 99:254-260, 1997.
25. Rocklin RE, Sheffer AL, Greineder DK, et al. Generation of antigenspecific suppressor cells during allergen desensitization N Engl J Med 302:1213-1219, 1980.
26. Alam R, Kuna P, Rozniecki J, et al. The magnitude of the spontaneous production of histamine releasing factor (HRF) by lympho cytes in vitro correlates with the state of bronchial hyperreactivity in patients with asthma. J Allergy Clin Immunol 79:103-108, 1987.
27. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92:644-651, 1993.
28. De Amici M, Puggioni F, Casali L. et al. Variations in serum levels of interleukin (IL)-1β, IL-2, IL-6 and tumor necrosis factor-α during specific immunotherapy. Ann Allergy Asthma Immunol 86.311-313, 2001.
29. Park H-S, Nahm D-H, Kim H-Y. et al. Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen Ann Allergy Asthma Immunol 86:444-448, 2001